Supplementary Results
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Supplementary Figure 1:
Structural comparison of inactive unphosphorylated ERK (left, pdb id: 1ERK) and active phosphorylated ERK (right, pdb id: 2ERK). Shown is a surface representation of the SCH772984-ERK complex with the bound inhibitor in yellow stick overlaid. The insets show the essential alterations of the P-loop and αC required for the accommodation of the inhibitor within the kinase.
Supplementary Figure 2:
Selectivity of SCH772984 across the human kinome using KINOMEScan assays. Competition binding using the inhibitor at 1µM concentration reveals high selectivity towards ERKs.
Supplementary Figure 3:
Enzyme kinetic data for the interaction of SCH772984 with ERK1/2 and its most relevant off targets. The dose response titration curves are generated using the with 500 nM for FR180204, for 4 hours and lysates were analysed using Western blotting before and after inhibitor wash out. Western blots band intensities were quantified and normalized relative to DMSO-treated cells and loading controls. Prolonged inhibition was not detected for FR180204 for which the ERK activity recovered within half an hour, consistent with the fast off-rate of this inhibitor measured in vitro. Quantification of Western blot signals for indicated phospho-proteins relative to loading controls is shown in the extrapolated recovery curves (lower panels) and reflects the recovery rates of MAPK pathway specific phosphorylation events. Uncut images of the exposed films used to generate the figure are shown on the right. Western Blots have been repeated twice with identical results.
Supplementary Figure 7:
Structural comparison of the ERK-SCH772984 complex with the inactive and active ERKs. Superimposition of ERK2-SCH772984 with inactive and active ERKs (left, pdb-id: 1ERK and 2ERK, respectively) and ERK1-SCH772984 with monophosphorylated ERK1 (right, pdb-id: 2ZOQ) reveals that while most parts of the kinase are highly static, slight structural alterations are evident for regions in proximity to the inhibitor binding pocket, including the P-loop site, and the activation segment αEF/αF loop, MAPK-specific insertion, L16 loop and C-terminal helix. Alterations of structural elements important for ERK-MEK and ERK dimerization are likely to provide a structural rational for the lack of ERK phosphorylation and activation in the presence of SCH772984. was added and the reaction mixture was stirred for 5 min. 85% o-Phosphoric acid (2 g) was added and the reaction mixture was stirred for 1 hr. The reaction mixture was extracted with EtOAc (3 x), washed with brine, dried (Na 2 SO 4 ), filtered and concentrated to give crude boronic acid, which was used directly without purification. The resulting boronic acid was dissolved in a 1:1 (v/v) mixture of DMF/water (50 mL). 2-Chloropyrimidine (1.05 g, 9.16 mmol) was added, followed by K 2 CO 3 (6.07 g, 44.0 mmol). The mixture was degased and purged with Ar. Pd(dppf) 2 CI 2 (600 mg, 0.733 mmol) was added and the reaction mixture was stirred at 80 °C for 8 hr. The mixture was cooled and diluted with water and extracted with EtOAc (2 x), dried (Na 2 SO 4 ), filtered and concentrated. The crude product was purified by flash chromatography on silica gel (0-60% EtOAc in hexane) to obtain the product as a white solid (1.95 g, 78% over two steps). 
Supplementary
Methyl (R)-1-(2-(tert-butoxy)-2-oxoethyl)pyrrolidine-3-carboxylate. R-Pyrrolidine-3-
carboxylic acid methyl ester (1.0 g, 6.0 mmol) was dissolved in DMF (30 ml). DIEA (3.2 ml, 18.0 mmol) was added, followed by Cs 2 CO 3 (2.93 g, 9.0 mmol). tert-Butyl bromoacetate (0.98 ml, 6.6 mmol) was added dropwise and the reaction mixture was stirred for 1 hr. The reaction mixture was diluted with water and extracted with EtOAc (3 x), dried (Na 2 SO 4 ), filtered and concentrated. The crude product was purified by flash chromatography on silica gel (0-70% EtOAc in hexane) to obtain the product as a white solid (1.37 g, 94%). The solution was concentrated to give crude (R)-2-(3-(methoxycarbonyl)pyrrolidin-1-yl)acetic acid, which was used without purification.
4-(4-Pyrimidin-2-yl-phenyl)-piperazine-1-carboxylic acid tert-butyl ester (1.32 g, 3.88 mmol) was dissolved in DCM (7 mL) and a 4 M solution of HCl in dioxane (7 mL) was added and stirred at rt for 2 hr. The reaction mixture was concentrated to give crude 2-(4-(piperazin-1-yl)phenyl)pyrimidine, which was used without purification.
The resulting (R)-2-(3-(methoxycarbonyl)pyrrolidin-1-yl)acetic acid and 2-(4-(piperazin-1-yl)phenyl)pyrimidine were dissolved in DMF (20 mL). 1-Hydroxybenztriazole (HOBT) (630 mg, 4.66 mmol), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCI) (970 mg, 5.00 mmol) and TEA (2.8 mL, 20 mmol) were added and stirred at rt overnight. The reaction mixture was diluted with EtOAc and washed with sat. NaHCO 3 , water, and brine.
The organic phase was dried (Na 2 SO 4 ), filtered and concentrated. The crude was purified by flash chromatography on silica gel (0-15% MeOH in DCM) to obtain the product as a yellow solid (1.21 g, 76% over two steps). mL, 10 mmol) was added, followed by HATU (760 mg, 2.0 mmol), and stirred at rt overnight.
The reaction mixture was diluted with EtOAc and washed with water and brine, dried (Na 2 SO 4 ), and concentrated. The crude was purified by flash chromatography on silica gel (0-15% MeOH in DCM) to obtain the product as a yellow solid (301 mg, 43% over two steps). . Saturated Na 2 CO 3 (0.2 mL) was added and the mixture was degassed and purged with Ar. Pd(dppf) 2 Cl 2 (1.2 mg, 0.0014 mmol) was added and stirred at 80 °C for 8 hr. The reaction mixture was cooled and diluted with a 4:1 solution of CHCl 3 /i-PrOH, and washed with water and brine. The organic layer was dried (Na 2 SO 4 ), filtered and concentrated. The crude was purified by HPLC (85%-5% water in MeOH with 0.5% TFA) to
give the product as a TFA salt (6.3 mg, 63%). 
